These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 36178589)

  • 1. Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?
    Geladaris A; Torke S; Weber MS
    CNS Drugs; 2022 Oct; 36(10):1019-1030. PubMed ID: 36178589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton's tyrosine kinase as a promising therapeutic target for multiple sclerosis.
    Saberi D; Geladaris A; Dybowski S; Weber MS
    Expert Opin Ther Targets; 2023; 27(4-5):347-359. PubMed ID: 37272515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis.
    Turner TJ; Brun P; Gruber RC; Ofengeim D
    Drugs R D; 2024 Jun; 24(2):263-274. PubMed ID: 38965189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair.
    Geladaris A; Torke S; Saberi D; Alankus YB; Streit F; Zechel S; Stadelmann-Nessler C; Fischer A; Boschert U; Häusler D; Weber MS
    Acta Neuropathol; 2024 Apr; 147(1):75. PubMed ID: 38656399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis.
    Steinmaurer A; Wimmer I; Berger T; Rommer PS; Sellner J
    Curr Pharm Des; 2022; 28(6):437-444. PubMed ID: 34218776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bruton's Tyrosine Kinase Inhibition in Multiple Sclerosis.
    Schneider R; Oh J
    Curr Neurol Neurosci Rep; 2022 Nov; 22(11):721-734. PubMed ID: 36301434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton's Tyrosine Kinase Inhibitors for Multiple Sclerosis Treatment: A New Frontier.
    Greenberg BM
    Neurol Clin; 2024 Feb; 42(1):155-163. PubMed ID: 37980113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations.
    Krämer J; Wiendl H
    Curr Opin Neurol; 2024 Jun; 37(3):237-244. PubMed ID: 38533819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease.
    Torke S; Pretzsch R; Häusler D; Haselmayer P; Grenningloh R; Boschert U; Brück W; Weber MS
    Acta Neuropathol; 2020 Oct; 140(4):535-548. PubMed ID: 32761407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the use of the Bruton Tyrosine Kinase inhibitors and the c-kit inhibitor masitinib result in clinically significant outcomes among patients with various forms of multiple sclerosis?
    Arsenault S; Benoit RY; Clift F; Moore CS
    Mult Scler Relat Disord; 2022 Nov; 67():104164. PubMed ID: 36126539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis.
    Nuesslein-Hildesheim B; Ferrero E; Schmid C; Huck C; Smith P; Tisserand S; Rubert J; Bornancin F; Eichlisberger D; Cenni B
    J Neuroinflammation; 2023 Aug; 20(1):194. PubMed ID: 37633912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
    Reich DS; Arnold DL; Vermersch P; Bar-Or A; Fox RJ; Matta A; Turner T; Wallström E; Zhang X; Mareš M; Khabirov FA; Traboulsee A;
    Lancet Neurol; 2021 Sep; 20(9):729-738. PubMed ID: 34418400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relation between BTK expression and iron accumulation of myeloid cells in multiple sclerosis.
    Steinmaurer A; Riedl C; König T; Testa G; Köck U; Bauer J; Lassmann H; Höftberger R; Berger T; Wimmer I; Hametner S
    Brain Pathol; 2024 Sep; 34(5):e13240. PubMed ID: 38254312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Bruton´s tyrosine kinase in different type of brain lesions of multiple sclerosis patients and during experimental demyelination.
    Elkjaer ML; Waede MR; Kingo C; Damsbo K; Illes Z
    Front Immunol; 2023; 14():1264128. PubMed ID: 38022591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors: A Review.
    Dybowski S; Torke S; Weber MS
    JAMA Neurol; 2023 Apr; 80(4):404-414. PubMed ID: 36780171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis.
    Airas L; Bermel RA; Chitnis T; Hartung HP; Nakahara J; Stuve O; Williams MJ; Kieseier BC; Wiendl H
    Ther Adv Neurol Disord; 2024; 17():17562864241233041. PubMed ID: 38638671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions.
    Mendes-Bastos P; Brasileiro A; Kolkhir P; Frischbutter S; Scheffel J; Moñino-Romero S; Maurer M
    Allergy; 2022 Aug; 77(8):2355-2366. PubMed ID: 35175630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis.
    Carnero Contentti E; Correale J
    Drug Des Devel Ther; 2022; 16():3473-3490. PubMed ID: 36238195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect on neutrophil migration and antimicrobial functions by the Bruton's tyrosine kinase inhibitors tolebrutinib, evobrutinib and fenebrutinib.
    De Bondt M; Renders J; de Prado PP; Berghmans N; Pörtner N; Vanbrabant L; de Oliveira VLS; Duran G; Baeten P; Broux B; Gouwy M; Matthys P; Hellings N; Struyf S
    J Leukoc Biol; 2024 Jul; ():. PubMed ID: 38976501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bruton tyrosine kinase inhibitors for multiple sclerosis.
    Krämer J; Bar-Or A; Turner TJ; Wiendl H
    Nat Rev Neurol; 2023 May; 19(5):289-304. PubMed ID: 37055617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.